All In Biotech

Drug Trial Radar · NCT06722235

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 171 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

171

Planned (sponsor's estimate)

Start

Feb 27, 2025

Primary completion

Mar 16, 2028

Study completion Mar 16, 2028

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Dec 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active ingredients in it. The participants will be treated with mezagitamab for up to 6 months. During the study, participants will visit their study clinic several times. Participants who complete the TAK-079-3002 study or do not have any response to study treatment by week 16 (according to study criteria) will be given the opportunity to participate in a continuation study to receive open label mezagitamab (if they are eligible and the site is able to open the continuation study).

Conditions

  • Immune Thrombocytopenic Purpura (ITP)

Interventions

  • MezagitamabDrug

    Mezagitamab injection administered SC.

  • PlaceboDrug

    Mezagitamab-matching placebo injection administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Durable Platelet ResponseTime frame: Up to Week 24

Locations

124 sites in 18 countries. Site status is shown where the registry gives one.

  • Genesis Cancer and Blood Institute - SCRI

    Hot Springs, Arkansas · Recruiting

  • USC Norris Comprehensive Cancer Center - Keck Medicine of USC

    Los Angeles, California · Recruiting

  • University of California San Diego Center for Bleeding and Clotting Disorders

    San Diego, California · Not yet recruiting

  • Rocky Mountain Cancer Center

    Denver, Colorado · Withdrawn

  • Georgetown University Medical Center - Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Innovative Hematology, Inc.

    Indianapolis, Indiana · Recruiting

  • The University of Iowa

    Iowa City, Iowa · Recruiting

  • University Of Louisville Brown Cancer Center

    Louisville, Kentucky · Recruiting

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts · Completed

  • MidAmerica Cancer Center

    Kansas City, Missouri · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Duke University Hospital

    Durham, North Carolina · Recruiting

  • East Carolina University

    Greenville, North Carolina · Recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Not yet recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program

    Philadelphia, Pennsylvania · Recruiting

  • Lewis Katz School of Medicine at Temple University

    Philadelphia, Pennsylvania · Recruiting

  • Baylor College of Medicine

    Houston, Texas · Recruiting

  • Virginia Oncology Associates

    Norfolk, Virginia · Recruiting

  • University of Washingto

    Seattle, Washington · Not yet recruiting

  • Versiti Wisconsin, Inc

    Milwaukee, Wisconsin · Recruiting

  • Canberra Hospital

    Garran, Australian Capital Territory, Australia · Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia · Recruiting

  • St George Hospital

    Kogarah, New South Wales, Australia · Recruiting

  • University of New South Wales (UNSW) - Liverpool Hospital - Liverpool Cancer Therapy Centre

    Liverpool, New South Wales, Australia · Recruiting

  • Westmead Hospital

    Westmead, New South Wales, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Monash University - Australian Centre for Blood Diseases (ACBD)

    Melbourne, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Fiona Stanley Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • Perth Blood Institute

    West Perth, Western Australia, Australia · Recruiting

  • Medical Center "Fama Medical"

    Plovdiv, Bulgaria · Active not recruiting

  • UMHAT Sv. Ivan Rilski

    Sofia, Bulgaria · Active not recruiting

  • UMHAT SofiaMed, OOD

    Sofia, Bulgaria · Active not recruiting

  • University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD

    Stara Zagora, Bulgaria · Active not recruiting

  • Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia

    Sofia, Sofia-Grad, Bulgaria · Active not recruiting

Showing 40 of 124 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.